IDDA.F INNATE PHARMA SP.ADR/1
- Market cap
- EUR 133M
- P/E
- -
- P/B
- 32.25x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is IDDA.F undervalued?
Graham numberThe Graham number of INNATE PHARMA SP.ADR/1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INNATE PHARMA SP.ADR/1 fundamental analysis
No fundamental analysis for INNATE PHARMA SP.ADR/1 yet.
INNATE PHARMA SP.ADR/1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…
Full company profileINNATE PHARMA SP.ADR/1 financial statements
INNATE PHARMA SP.ADR/1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 12.1M | 49.6M | 51.9M | 12.6M | 2.79M |
| Operating Income | -47.8M | -16.4M | -12.7M | -51.6M | -53.4M |
| EBITDA | - | -12.3M | -5.55M | -46.9M | -43.6M |
| Net Income | -52.8M | -58.1M | -7.57M | -49.5M | -49.2M |
| EPS | -0.66 | -0.73 | -0.09 | -0.59 | -0.52 |
| Balance Sheet | |||||
| Total Assets | 267M | 199M | 175M | 111M | 62.7M |
| Total Liabilities | 160M | 145M | 123M | 102M | 84.4M |
| Shareholders' Equity | 107M | 54.2M | 51.9M | 8.83M | -21.7M |
| Cash & Short-term Investments | 104M | 84.2M | 70.6M | 66.4M | 28.1M |
| Cash Flow | |||||
| Operating Cash Flow | -58.5M | -19.2M | -32.6M | -6.90M | -32.6M |
| Capital Expenditure | 1.33M | 1.12M | 2.35M | 391K | 2.35M |
| Free Cash Flow | -59.8M | -20.3M | -34.9M | -7.29M | -34.9M |
| Ratios | |||||
| ROE | -49.2% | -107.3% | -14.6% | -560.0% | - |
| ROA | -19.7% | -29.2% | -4.3% | -44.5% | -78.4% |
| Net Profit Margin | -436.1% | -117.2% | -14.6% | -392.0% | -1,764.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INNATE PHARMA SP.ADR/1 dividends
INNATE PHARMA SP.ADR/1 has not paid dividends in the last 5 fiscal years.
Who owns INNATE PHARMA SP.ADR/1
- Insiders 1.40%
- Institutions 0.35%
- Public & others 98.25%
- Shares outstanding 112M
- Free float 68.9M
INNATE PHARMA SP.ADR/1 company profile
- Company name
- INNATE PHARMA SP.ADR/1
- Ticker
- IDDA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- December
- Address
- 117, Avenue de Luminy, Marseille, France, 13009
- Phone
- 33 4 30 30 30 30
- Website
- innate-pharma.com
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
INNATE PHARMA SP.ADR/1 management
10- Mr. Jonathan E. Dickinson B.Sc., M.B.A.CEO & Director · born 1968
- Mr. Yannis Morel Ph.D.Executive VP & COO · born 1973
- Dr. François Romagné Ph.D.Founder · born 1964
- Dr. Marc Bonneville Ph.D.Founder · born 1960
- Mr. Jean Jacques Fournié Ph.D.Founder
- Mr. Alessandro Moretta M.D., Ph.D.Founder
- Mr. Frederic Lombard M.B.A.Senior VP & CFO · born 1975
- Ms. Stephanie CornenVice President of Investor Relations, Communication & Commercial Strategy · born 1987
- Ms. Odile BelzunceVP, Chief of Compliance & Operations Officer and Interim Head of HR · born 1980
- Ms. Claire de Saint BlanquatVP of Legal & Corporate Affairs and Secretary of the Supervisory Board · born 1973